Skip to main content

Glasdegib Side Effects

Medically reviewed by Drugs.com. Last updated on Apr 16, 2023.

Applies to glasdegib: oral tablet.

Warning

Oral route (Tablet)

Warning: Embryo-Fetal ToxicityGlasdegib can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. Glasdegib is embryotoxic, fetotoxic, and teratogenic in animals. Conduct pregnancy testing in females of reproductive potential prior to initiation of glasdegib treatment. Advise females of reproductive potential to use effective contraception during treatment with glasdegib and for at least 30 days after the last dose. Advise males of the potential risk of glasdegib exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with glasdegib and for at least 30 days after the last dose to avoid potential drug exposure.

Serious side effects of Glasdegib

Along with its needed effects, glasdegib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking glasdegib:

More common

Other side effects of Glasdegib

Some side effects of glasdegib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to glasdegib: oral tablet.

Hematologic

Very common (10% or more): Anemia (43%), hemorrhage (e.g., petechiae, epistaxis, hematoma, contusion, rectal hemorrhage, anal hemorrhage, ecchymosis, gingival bleeding, hematuria, mouth hemorrhage, purpura, cerebral hemorrhage, eye contusion, eye hemorrhage, gastric hemorrhage, GI hemorrhage, hematemesis, hemoptysis, implant site hematoma, injection site bruising, retroperitoneal hematoma, thrombotic thrombocytopenic purpura, tracheal hemorrhage, conjunctival hemorrhage, disseminated intravascular coagulation, eyelid hematoma, hematochezia, hemorrhage intracranial, hemorrhoidal hemorrhage, lower GI hemorrhage, retinal hemorrhage, subdural hematoma) (36%), febrile neutropenia (31%0, thrombocytopenia (30%), platelet count decreased (15%), white blood cell count decreased (11%)[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (e.g., pain in extremity, arthralgia, back pain, myalgia, musculoskeletal pain, musculoskeletal chest pain, neck pain, bone pain (30%), creatine phosphokinase (CPK) increased (16%), muscle tightness/spasm (15%)[Ref]

Metabolic

Very common (10% or more): Hyponatremia (54%), hypomagnesemia (33%), edema (e.g., edema peripheral, edema, fluid overload, fluid retention, swelling face) (30%), decreased appetite (21%), hypokalemia (15%), weight loss (13%)[Ref]

Hepatic

Very common (10% or more): AST increased (28%), alkaline phosphatase increased (23%)[Ref]

Respiratory

Very common (10% or more): Dyspnea (e.g., dyspnea, hypoxia, bronchospasm, respiratory failure (23%), pneumonia (e.g., pneumonia, pneumonia aspiration, lung infection) (19%), cough (18%)[Ref]

Other

Very common (10% or more): Asthenia/fatigue (36%), pyrexia (18%)[Ref]

Nervous system

Very common (10% or more): Dysgeusia/ageusia (21%), dizziness (18%), headache (12%)[Ref]

Renal

Very common (10% or more): Creatinine increased (96%), renal insufficiency (e.g., acute kidney injury, blood creatinine increased, oliguria, renal failure) (19%)[Ref]

Cardiovascular

Very common (10% or more): Atrial arrhythmia (e.g., atrial fibrillation, bradycardia, tachycardia, sinus tachycardia) (13%), chest pain (e.g., chest pain, non-cardiac chest pain) (12%)

Common (1% to 10%): QT interval prolongation[Ref]

Dermatologic

Very common (10% or more): Rash (e.g., rash, pruritus, erythema, skin ulcer, rash maculopapular, rash pruritic (20%)

Common (1% to 10%): Alopecia[Ref]

Gastrointestinal

Very common (10% or more): Nausea (29%), mucositis (e.g., mucosal inflammation, oropharyngeal pain, stomatitis, anal ulcer, gingival pain, laryngeal inflammation, esophagitis, oral pain, aphthous ulcer, mouth ulceration, pharyngeal inflammation) (21%), constipation (20%), diarrhea (18%), vomiting (18%)

Common (1% to 10%): Loose tooth, toothache[Ref]

Frequently asked questions

References

1. Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group. 2018.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.